BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19602475)

  • 1. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE).
    Schiffer L; Kümpers P; Davalos-Misslitz AM; Haubitz M; Haller H; Anders HJ; Witte T; Schiffer M
    Nephrol Dial Transplant; 2009 Dec; 24(12):3708-12. PubMed ID: 19602475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
    Ezzat M; El-Gammasy T; Shaheen K; Shokr E
    Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of serum CXCL13 in SLE as well as in sepsis.
    Schiffer L; Kielstein JT; Haubitz M; Lührs H; Witte T; Haller H; Kümpers P; Schiffer M
    Lupus; 2011 Apr; 20(5):507-11. PubMed ID: 21078761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
    Lee HT; Shiao YM; Wu TH; Chen WS; Hsu YH; Tsai SF; Tsai CY
    J Rheumatol; 2010 Jan; 37(1):45-52. PubMed ID: 19955043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell-attracting chemokine-1 (BCA-1/CXCL13) in systemic lupus erythematosus, its correlation to disease activity and renal involvement.
    Hafez SS; Saad Wel S; Shedid NH
    Egypt J Immunol; 2014; 21(2):23-32. PubMed ID: 25812350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.
    Kümpers P; David S; Haubitz M; Hellpap J; Horn R; Bröcker V; Schiffer M; Haller H; Witte T
    Ann Rheum Dis; 2009 Oct; 68(10):1638-43. PubMed ID: 18930996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
    Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
    Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
    Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
    J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares.
    Amoura Z; Combadiere C; Faure S; Parizot C; Miyara M; Raphaël D; Ghillani P; Debre P; Piette JC; Gorochov G
    Arthritis Rheum; 2003 Dec; 48(12):3487-96. PubMed ID: 14673999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
    Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis.
    Chan RW; Lai FM; Li EK; Tam LS; Wong TY; Szeto CY; Li PK; Szeto CC
    Arthritis Rheum; 2004 Sep; 50(9):2882-90. PubMed ID: 15457456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
    Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
    Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
    Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
    Heshmat NM; El-Kerdany TH
    Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
    Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
    Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.